A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients
This study is to evaluate the safety, tolerability, clinical efficacy and pharmacokinetics of continuous Endostar intravenous infusion combined with pemetrexed and carboplatin in advanced non small cell lung cancer (NSCLC) patients.
Non-Small Cell Lung Cancer
DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Endostar|DRUG: Centrum
Dose Limiting Toxicity, up to 21 days
Objective Response Rate, up to 6 cycles|Disease Control Rate, up to 6 cycles|Progression-free Survival, up to 2 years|Overall Survival, up to 2 years
This study is to evaluate the safety, tolerability, clinical efficacy and pharmacokinetics of continuous Endostar intravenous infusion combined with pemetrexed and carboplatin in advanced non small cell lung cancer (NSCLC) patients.